Emcure Pharmaceuticals
Emcure Pharmaceuticals Share Price Chart
Emcure Pharmaceuticals last traded at ₹1,868.30 (2026-10-13). Over the past month the stock moved -5.0%, three months the stock moved +10.0%, year the stock moved +31.3%. Its closing range over 52 weeks is ₹1,318.90 – ₹2,015.75, with the latest close 7.3% below the high.
Closing prices up to 2026-10-13.
About Emcure Pharmaceuticals
Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally[1]
Business Overview:[1][2] EPL develops, manufactures and markets a broad range of pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs, including chiral molecules, iron molecules and cytotoxic products. It has a presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV etc. Company has 350+ brands, with a wide network across 70+ countries.
Fundamentals
Quarterly Results
In the latest quarter (Jun 2026), Emcure Pharmaceuticals reported sales of ₹2,580.00 crore (+22.8%) and net profit of ₹292.00 crore (+35.8%), compared with the same quarter last year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Jun 2026 | 2,580 | 532.00 | 21.00 | 292.00 | 15.50 |
| Mar 2026 | 2,470 | 480.00 | 19.00 | 244.00 | 12.84 |
| Dec 2025 | 2,363 | 493.00 | 21.00 | 231.00 | 12.16 |
| Sep 2025 | 2,270 | 475.00 | 21.00 | 251.00 | 12.84 |
| Jun 2025 | 2,101 | 417.00 | 20.00 | 215.00 | 10.92 |
| Mar 2025 | 2,116 | 402.00 | 19.00 | 197.00 | 9.97 |
| Dec 2024 | 1,963 | 355.00 | 18.00 | 156.00 | 8.11 |
| Sep 2024 | 2,002 | 381.00 | 19.00 | 202.00 | 10.29 |
| Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Sales growth | +20.4% | +17.7% | +19.5% | +15.8% | +13.4% | +20.4% | +16.7% | +22.8% |
| Operating profit growth | +15.8% | +20.7% | +29.3% | +24.1% | +24.7% | +38.9% | +19.4% | +27.6% |
| Net profit growth | +38.4% | +30.0% | +62.8% | +40.5% | +24.3% | +48.1% | +23.9% | +35.8% |
| EPS growth | +33.8% | +29.3% | +56.8% | +37.4% | +24.8% | +49.9% | +28.8% | +41.9% |
| OPM % | 19.0% | 18.0% | 19.0% | 20.0% | 21.0% | 21.0% | 19.0% | 21.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Annual Financials
In the latest year (Mar 2026), Emcure Pharmaceuticals reported sales of ₹9,204.00 crore (+16.6%) and net profit of ₹941.00 crore (+33.1%), compared with the previous year.
| Period | Sales | Operating profit | OPM % | Net profit | EPS (₹) |
|---|---|---|---|---|---|
| Mar 2026 | 9,204 | 1,865 | 20.00 | 941.00 | 48.76 |
| Mar 2025 | 7,896 | 1,474 | 19.00 | 707.00 | 35.96 |
| Mar 2024 | 6,658 | 1,230 | 18.00 | 528.00 | 27.50 |
| Mar 2023 | 5,986 | 1,182 | 20.00 | 562.00 | 29.42 |
| Mar 2022 | 5,855 | 1,330 | 23.00 | 703.00 | 36.62 |
| Mar 2021 | 5,033 | 1,216 | 24.00 | 419.00 | 23.15 |
| Mar 2020 | 5,049 | 708.00 | 14.00 | 101.00 | 4.62 |
| Mar 2019 | 4,717 | 749.00 | 16.00 | 209.00 | 10.79 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales growth | +7.0% | -0.3% | +16.3% | +2.2% | +11.2% | +18.6% | +16.6% |
| Operating profit growth | -5.5% | +71.8% | +9.4% | -11.1% | +4.1% | +19.8% | +26.5% |
| Net profit growth | -51.7% | +314.9% | +67.8% | -20.1% | -6.0% | +33.9% | +33.1% |
| EPS growth | -57.2% | +401.1% | +58.2% | -19.7% | -6.5% | +30.8% | +35.6% |
| OPM % | 14.0% | 24.0% | 23.0% | 20.0% | 18.0% | 19.0% | 20.0% |
Colour scale: below -5% -5% to 0% 0% to 5% 5% to 20% 20% and above. A dash means the earlier figure was zero or negative, so a percentage is not meaningful.
Shareholding
AI Analysis
No AI analysis generated yet for Emcure Pharmaceuticals.
Get Free AI Stock Analysis FREE →Latest News
-
Emcure Pharma up over 3% as board approves merger of two subsidiaries - Business Standard
-
Emcure Pharma up over 3% as board approves merger of two subsidiaries - Business Standard
-
Emcure Pharma up over 3% as board approves merger of two subsidiaries - Business Standard
-
Emcure Pharma up over 3% as board approves merger of two subsidiaries - Business Standard
-
Price Band Hitters, September 18, 2026 at 3:30 PM IST: Emcure Pharmaceuticals LeadsThe List
-
Emcure Pharmaceuticals files FY26 sustainability report with stock exchanges - scanx.trade
-
Emcure Pharmaceuticals files FY26 sustainability report with stock exchanges - scanx.trade
-
Emcure Pharmaceuticals moves up on getting EIR from USFDA for Sanand facility
-
ICMR licenses cancer, vaccine technologies to Emcure, Biological E - The Economic Times
-
ICMR licenses cancer, vaccine technologies to Emcure, Biological E - The Economic Times
Frequently Asked Questions
What is Emcure Pharmaceuticals's current stock price?
Emcure Pharmaceuticals shares were last quoted at ₹1,868.30 (+1.9% on the day). Use the Refresh price button on this page for the latest available price. Prices are for information only.
What is the P/E ratio of Emcure Pharmaceuticals?
Emcure Pharmaceuticals has a price-to-earnings (P/E) ratio of 36.49 and a price-to-book (P/B) ratio of 7.04. The industry P/E is 53.33.
What is the 52-week high and low of Emcure Pharmaceuticals?
The 52-week high of Emcure Pharmaceuticals is ₹2,101.00 and the 52-week low is ₹1,260.10.
What is the market cap of Emcure Pharmaceuticals?
The market capitalisation of Emcure Pharmaceuticals is about ₹36,901.57 crore.
How did Emcure Pharmaceuticals perform in its latest quarterly results?
In the latest quarter (Jun 2026), Emcure Pharmaceuticals reported sales of ₹2,580.00 crore (+22.8%) and net profit of ₹292.00 crore (+35.8%), compared with the same quarter last year.
Is Emcure Pharmaceuticals a good stock to buy?
This page is for information and is not investment advice. As per the data shown here, Emcure Pharmaceuticals has a 3-year ROE of 19.00%, 3-year profit growth of 21.00%. Review the fundamentals, quarterly results and AI analysis on StockSpin, and consult a SEBI-registered adviser before investing.
What is the promoter holding in Emcure Pharmaceuticals?
Promoters hold about 77.83% of Emcure Pharmaceuticals.
Which sector does Emcure Pharmaceuticals belong to?
Emcure Pharmaceuticals belongs to the Pharmaceuticals & Drugs sector.